Announcements Trials
Browse Landscape

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Observational 3

Sponsor

Conditions

Breast Neoplasms 468Neoplasms 316Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 208Lung Neoplasms 178Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 60Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

Data Collection 2human papillomavirus vaccine, L1 type 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Abortion, Spontaneous × Clear all
NCT01653392 2024-03-15

BioThrax® (Anthrax) Vaccine in Pregnancy Registry

Emergent BioSolutions

Completed
98 enrolled

Congenital Abnormalities, Abortion, Spontaneous, Birth Weight, Eclampsia, Fetal Death, Hydatidiform Mole, Obstetric Labor, Premature, Pre-Eclampsia, Pregnancy Complications, Pregnancy, Ectopic, Diabetes, Gestational, Premature Birth, Stillbirth, Maternal Death

NCT01290393 2018-07-26

Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

GlaxoSmithKline

Terminated
2 enrolled

Abortion, Spontaneous, Papillomavirus Infections

NCT01905462 2013-09-30

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK

GlaxoSmithKline

Completed
1,046 enrolled

Abortion, Spontaneous, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡